Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition
暂无分享,去创建一个
Amy Young | M. Belvin | K. Hoeflich | L. Friedman | J. Chan | D. Kirkpatrick | C. Bakalarski | Lilian Phu | Klaus P. Hoeflich | Jocelyn Chan | Marcia Belvin | Donald S. Kirkpatrick | Daisy J. Bustos | Taner Dogan | Lilian Phu | Lori S. Friedman | Qinghua Song | Corey E. Bakalarski | Taner Dogan | Amy E. Young | Qinghua Song
[1] J. Downward. Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.
[2] J. Rush,et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells , 2005, Nature Biotechnology.
[3] M. Belvin,et al. GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway , 2011, Molecular Cancer Therapeutics.
[4] M. Lavin,et al. ATM Activation by Oxidative Stress , 2010, Science.
[5] J. Sebolt-Leopold,et al. Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.
[6] S. T. Kim,et al. Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members* , 1999, The Journal of Biological Chemistry.
[7] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[8] Matthias Mann,et al. Unbiased RNA–protein interaction screen by quantitative proteomics , 2009, Proceedings of the National Academy of Sciences.
[9] Gunther Schadow,et al. Protein quantification in label-free LC-MS experiments. , 2009, Journal of proteome research.
[10] S. Lees-Miller,et al. DNA-PK: the means to justify the ends? , 2008, Advances in immunology.
[11] David J. Chen,et al. ATM-Dependent and -Independent Dynamics of the Nuclear Phosphoproteome After DNA Damage , 2010, Science Signaling.
[12] P. Pandolfi,et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.
[13] P. Cohen,et al. Mechanism of activation of protein kinase B by insulin and IGF‐1. , 1996, The EMBO journal.
[14] Gary Box,et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.
[15] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[16] J. Blenis,et al. SKAR Links Pre-mRNA Splicing to mTOR/S6K1-Mediated Enhanced Translation Efficiency of Spliced mRNAs , 2008, Cell.
[17] Dexin Kong,et al. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. , 2009, Biological & pharmaceutical bulletin.
[18] T. Misteli,et al. Activation of the Cellular DNA Damage Response in the Absence of DNA Lesions , 2008, Science.
[19] Lei He,et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.
[20] Ruedi Aebersold,et al. Statistical protein quantification and significance analysis in label-free LC-MS experiments with complex designs , 2012, BMC Bioinformatics.
[21] Mark Merchant,et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. , 2012, Cancer research.
[22] Wei Zhou,et al. In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.
[23] David J. Chen,et al. DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. , 2006, DNA repair.
[24] D. H. Larsen,et al. Site-specific Phosphorylation Dynamics of the Nuclear Proteome during the DNA Damage Response* , 2010, Molecular & Cellular Proteomics.
[25] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[26] R. de Cabo,et al. AsSIRTing the DNA damage response. , 2008, Trends in cell biology.
[27] B. A. Ballif,et al. ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage , 2007, Science.
[28] S. Burma,et al. The Dual PI 3 K / mTOR Inhibitor NVP-BEZ 235 Is a Potent Inhibitor of ATM-and DNA-PKCs-Mediated DNA Damage Responses 1 , 2 , 2014 .
[29] W. Sellers,et al. Drug discovery approaches targeting the PI3K/Akt pathway in cancer , 2008, Oncogene.
[30] S. Burma,et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. , 2012, Neoplasia.
[31] K. Moelling,et al. Phosphorylation and regulation of Raf by Akt (protein kinase B). , 1999, Science.
[32] S. Gygi,et al. Profiling of UV-induced ATM/ATR signaling pathways , 2007, Proceedings of the National Academy of Sciences.
[33] Steven P Gygi,et al. The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. , 2008, Journal of proteome research.
[34] Steven P Gygi,et al. Akt–RSK–S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases , 2010, Science Signaling.
[35] S. Opiyo,et al. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress , 2012, Nucleic acids research.
[36] C. Der,et al. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.
[37] J. Sarkaria,et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. , 1998, Cancer research.
[38] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[39] Katheryn Meek,et al. Chapter 2 DNA-PK , 2008 .
[40] I. Cristea,et al. Functional Proteomics Establishes the Interaction of SIRT7 with Chromatin Remodeling Complexes and Expands Its Role in Regulation of RNA Polymerase I Transcription* , 2011, Molecular & Cellular Proteomics.
[41] Steven P Gygi,et al. A probability-based approach for high-throughput protein phosphorylation analysis and site localization , 2006, Nature Biotechnology.
[42] J. Avruch,et al. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. , 2001, Physiological reviews.
[43] B. Hemmings,et al. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. , 2008, Molecular cell.
[44] J. Dodge,et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. , 1994, Cancer research.
[45] Qi Ding,et al. trans Autophosphorylation at DNA-Dependent Protein Kinase's Two Major Autophosphorylation Site Clusters Facilitates End Processing but Not End Joining , 2007, Molecular and Cellular Biology.
[46] Timothy Woods,et al. Autophosphorylation of the Catalytic Subunit of the DNA-Dependent Protein Kinase Is Required for Efficient End Processing during DNA Double-Strand Break Repair , 2003, Molecular and Cellular Biology.